Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

• DOI: 10.1007/s12325-020-01498-5
• Publication Date: 2020-09-25T05:02:22Z
• Authors: Hoda Taheri; Mojtaba Malek; Faramarz Ismail-B...; Farhad Zamani; Masoudreza Sohrabi; Mohammad Reza babaei; Mohammad E. Khamseh
• Keywords: Steatosis; Empagliflozin; Transient elastography

Despite the high prevalence of non-alcoholic fatty liver disease (NAFLD) and its associated co-morbidities, no efficient treatment in a percentage individuals is available. Beneficial effects sodium–glucose co-transporter 2 inhibitors on have been investigated people with type diabetes (T2DM). The aim this study was to explore effect empagliflozin steatosis fibrosis patients NAFLD without T2DM. In prospective randomized, double-blind, placebo-controlled clinical trial, participants were randomized (10 mg/day) (n = 43) or placebo 47) for 24 weeks. Hepatic assessed using transient elastography measure controlled attenuation parameter (CAP) stiffness measurement (LSM). primary outcome change CAP score at There significant decrease both groups but difference observed between two (P 0.396). LSM significantly decreased empagliflozin-treated group (6.03 ± 1.40 5.33 1.08 kPa; P 0.001), while found group. subgroups analysis baseline (CAP ≥ 302 dB/m), improved (37.2% vs. 17%; 0.035). grade fat visual ultrasound images, AST, ALT, fasting insulin levels group, changes Empagliflozin improves and, more importantly, measures ClinicalTrials.gov identifier, IRCT20190122042450N1.